Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANP in Hypertension and Metabolic Syndrome
NCT03781739Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Aug 2017
- Primary completion
- Nov 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertension (HTN) and metabolic syndrome comparing MANP with Placebo (2 arms). Primary endpoints: Cardiovascular Outcome at 24 hours, Second Messenger at 24 hours and 1 more. Started Aug 2017; status: completed.
02
Drugs
M-atrial natriuretic peptide
03
Conditions
hypertension (HTN)metabolic syndrome
Beyond the preview
Go deeper on NCT03781739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781739.